Wall Street’s Unpopular Stock Picks: Buy Pfizer and Federated Hermes, Avoid Merck

Wall Street analysts are taking a cautious stance on several well-known stocks, a move that is relatively rare given the industry’s usual reluctance to criticize companies due to potential conflicts with other business lines like mergers and acquisitions. At StockStory, we conduct independent analyses to determine if these negative forecasts are justified. Our findings highlight two stocks where pessimism may present a buying opportunity and one where skepticism appears well-founded.

Merck (NYSE: MRK), a pharmaceutical giant with a history dating back to 1891, is currently facing challenges. Its underwhelming revenue performance over the past two years and rising expenses as a percentage of revenue have raised concerns. The company’s earnings per share have declined by 11.1% annually over the last five years, despite revenue growth. With a stock price of $139.65 and a forward P/E ratio of 16.9x, Merck may not be the best investment option at this time.

On the other hand, Pfizer (NYSE: PFE) stands out as a promising investment. The company, founded in 1849, boasts unparalleled scale with $63.7 billion in revenue, providing it with strong negotiating leverage and industry staying power. Pfizer’s adjusted operating profits and efficiency have improved over the last two years, and it boasts an industry-leading 17.5% return on capital. Trading at $27.43 per share, or 10x forward P/E, Pfizer could be an attractive option for investors.

Federated Hermes (NYSE: FHI), an investment management firm with roots dating back to 1955, also shows strong potential. The company has demonstrated respectable annualized sales growth of 10.2% over the last two years, with share buybacks driving earnings per share growth of 21.1%. Its stellar return on equity highlights management’s ability to identify highly profitable ventures. At $56.75 per share, or 9.7x forward P/E, Federated Hermes could be a good time to buy.